Unraveling Alzheimer’s: Making Sense of the Relationship between Diabetes and Alzheimer’s Disease

Numerous studies have documented a strong association between diabetes and Alzheimer’s disease (AD). The nature of the relationship, however, has remained a puzzle, in part because of seemingly incongruent findings. For example, some studies have concluded that insulin deficiency is primarily at fault, suggesting that intranasal insulin or inhibiting the insulin-degrading enzyme (IDE) could be beneficial. Other research has concluded that hyperinsulinemia is to blame, which implies that intranasal insulin or the inhibition of IDE would exacerbate the disease. Such antithetical conclusions pose a serious obstacle to making progress on treatments. However, careful integration of multiple strands of research, with attention to the methods used in different studies, makes it possible to disentangle the research on AD. This integration suggests that there is an important relationship between insulin, IDE, and AD that yields multiple pathways to AD depending on the where deficiency or excess in the cycle occurs. I review evidence for each of these pathways here. The results suggest that avoiding excess insulin, and supporting robust IDE levels, could be important ways of preventing and lessening the impact of AD. I also describe what further tests need to be conducted to verify the arguments made in the paper, and their implications for treating AD.

[1]  C. Hölscher,et al.  Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence , 2013, CNS Drugs.

[2]  R. Stewart,et al.  Type 2 diabetes mellitus, cognitive impairment and dementia , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[3]  T. Montine,et al.  Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. , 2005, Archives of neurology.

[4]  L. V. Van Eldik,et al.  Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin , 2014, Molecular Neurodegeneration.

[5]  H. Lipp,et al.  Lack of neprilysin suffices to generate murine amyloid‐like deposits in the brain and behavioral deficit in vivo , 2006, Journal of neuroscience research.

[6]  Tao Wang,et al.  Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model , 2010, Molecular Neurodegeneration.

[7]  F. Hamel,et al.  Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation. , 2009, Biochemical pharmacology.

[8]  A. Dedeoglu,et al.  Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease , 2014, Molecular Psychiatry.

[9]  L. Hersh,et al.  Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  L. Hersh,et al.  Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.

[11]  R. Mayeux,et al.  Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. , 2001, American journal of epidemiology.

[12]  Prasanthi,et al.  Molecular Neurodegeneration Differential Effects of 24-hydroxycholesterol and 27-hydroxycholesterol on Β-amyloid Precursor Protein Levels and Processing in Human Neuroblastoma Sh-sy5y Cells , 2022 .

[13]  M. Leissring,et al.  Deletion of Insulin-Degrading Enzyme Elicits Antipodal, Age-Dependent Effects on Glucose and Insulin Tolerance , 2011, PloS one.

[14]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[15]  J. Mcdermott,et al.  Degradation of Alzheimer's ß-Amyloid Protein by Human and Rat Brain Peptidases: Involvement of Insulin-Degrading Enzyme , 2004, Neurochemical Research.

[16]  W. Duckworth Insulin degradation: mechanisms, products, and significance. , 1988, Endocrine reviews.

[17]  G. Wilcock,et al.  Hyperinsulinaemia and Alzheimer's disease. , 1994, Age and ageing.

[18]  M. Leissring,et al.  Proteolytic degradation of amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.

[19]  A. Boschero,et al.  Reduced insulin clearance and lower insulin-degrading enzyme expression in the liver might contribute to the thrifty phenotype of protein-restricted mice , 2014, British Journal of Nutrition.

[20]  P. O'Brien,et al.  Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.

[21]  D. Selkoe,et al.  Degradation of Amyloid -Protein by a Serine Protease--Macroglobulin Complex (*) , 1996, The Journal of Biological Chemistry.

[22]  R. Au,et al.  Positive association between plasma amylin and cognition in a homebound elderly population. , 2014, Journal of Alzheimer's disease : JAD.

[23]  A. Korczyn Why Have We Failed to Cure Alzheimer's Disease? , 2014, Neurobiology of Aging.

[24]  D. Bennett,et al.  LONG-TERM FETAL CELL TRANSPLANT IN HUNTINGTON DISEASE: STAYIN’ ALIVE , 2007, Neurology.

[25]  S. Resnick,et al.  Midlife adiposity predicts earlier onset of Alzheimer’s dementia, neuropathology and presymptomatic cerebral amyloid accumulation , 2015, Molecular Psychiatry.

[26]  Y. Itzhak,et al.  Long-term parental methamphetamine exposure of mice influences behavior and hippocampal DNA methylation of the offspring , 2014, Molecular Psychiatry.

[27]  W. Qiu,et al.  Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease? , 2014, Front. Aging Neurosci..

[28]  S. Craft,et al.  Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice , 2006, Experimental Neurology.

[29]  Qian-kun Quan,et al.  Ginsenoside Rg1 Decreases Aβ1–42 Level by Upregulating PPARγ and IDE Expression in the Hippocampus of a Rat Model of Alzheimer's Disease , 2013, PloS one.

[30]  W. Duckworth,et al.  Degradation of Amylin by Insulin-degrading Enzyme* , 2000, The Journal of Biological Chemistry.

[31]  B. Winblad,et al.  P4-040 Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study , 2004, Neurobiology of Aging.

[32]  P. van Endert,et al.  Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice , 2015, Nature Communications.

[33]  L. Schneider,et al.  Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials , 2007, The Lancet Neurology.

[34]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[35]  A Hofman,et al.  Diabetes mellitus and the risk of dementia , 1999, Neurology.

[36]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[37]  D. Selkoe,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Zmijewska,et al.  Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin Deficiency , 2006, Diabetes.

[39]  Nathan Herrmann,et al.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[40]  D. Bennett,et al.  Diabetes is related to cerebral infarction but not to AD pathology in older persons , 2006, Neurology.

[41]  P. Mehta,et al.  Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.

[42]  Eileen Crimmins,et al.  The Value of Delaying Alzheimer’s Disease Onset , 2014, Forum for health economics & policy.

[43]  R. Dankner,et al.  Insulin Resistance and Hyperinsulinemia , 2008, Diabetes Care.

[44]  P. Wittung-Stafshede,et al.  Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner , 2015, Scientific Reports.

[45]  B. Winblad,et al.  Diabetes mellitus and risk of dementia in the Kungsholmen project , 2004, Neurology.

[46]  M. MacCoss,et al.  Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism , 2006 .

[47]  S. Rai,et al.  Glial activation and post-synaptic neurotoxicity: The key events in Streptozotocin (ICV) induced memory impairment in rats , 2014, Pharmacology Biochemistry and Behavior.

[48]  G. Schellenberg,et al.  Reduced Hippocampal Insulin-Degrading Enzyme in Late-Onset Alzheimer's Disease Is Associated with the Apolipoprotein E-ε4 Allele , 2003 .

[49]  G. Zuliani,et al.  Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels. , 1999, Dementia and geriatric cognitive disorders.

[50]  G. Schellenberg,et al.  Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.

[51]  Paco Martorell,et al.  Monetary costs of dementia in the United States. , 2013, The New England journal of medicine.

[52]  M. Ingelsson,et al.  In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. , 2015, The American journal of pathology.

[53]  L. Launer,et al.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.

[54]  D. Alkon,et al.  Role of insulin and insulin receptor in learning and memory , 2001, Molecular and Cellular Endocrinology.

[55]  D. Selkoe,et al.  Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme , 2000, The Journal of Neuroscience.

[56]  J. Wands,et al.  Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. , 2005, Journal of Alzheimer's disease : JAD.

[57]  H. Hamazaki Cathepsin D is involved in the clearance of Alzheimer's β‐amyloid protein , 1996 .

[58]  Lixia Guo,et al.  Geniposide regulates insulin-degrading enzyme expression to inhibit the cytotoxicity of Aβ₁₋₄₂ in cortical neurons. , 2012, CNS & neurological disorders drug targets.

[59]  R. Mayeux,et al.  Hyperinsulinemia and risk of Alzheimer disease , 2004, Neurology.

[60]  S. M. de la Monte Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease , 2012, Current Alzheimer research.

[61]  A. Hofman,et al.  312 Incidence of Alzheimer's disease and vascular dementia in the Rotterdam study , 1996, Neurobiology of Aging.

[62]  C. Eckman,et al.  Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention , 2005 .

[63]  C. Eckman,et al.  Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme* , 2001, The Journal of Biological Chemistry.

[64]  T. Montine,et al.  Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .

[65]  S. Love,et al.  A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease , 2011, Journal of neuropathology and experimental neurology.

[66]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[67]  D. Selkoe,et al.  Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. , 1996, Journal of Biological Chemistry.

[68]  M. Leissring,et al.  Insulin-degrading enzyme is exported via an unconventional protein secretion pathway , 2009, Molecular Neurodegeneration.

[69]  M. Leissring,et al.  Regulation of distinct pools of amyloid β-protein by multiple cellular proteases , 2013, Alzheimer's Research & Therapy.

[70]  I. Kurochkin,et al.  Alzheimer's β‐amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme , 1994, FEBS letters.

[71]  B. Teter,et al.  Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention , 2004, The Journal of Neuroscience.

[72]  J. Baird,et al.  Diabetes mellitus and obesity , 1973, Proceedings of the Nutrition Society.

[73]  C. Soto,et al.  Cross-Seeding of Misfolded Proteins: Implications for Etiology and Pathogenesis of Protein Misfolding Diseases , 2013, PLoS pathogens.

[74]  K. Akiyama,et al.  Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type , 1991, Biological Psychiatry.

[75]  Chunyu Wang,et al.  γ-Secretase Substrate Concentration Modulates the Aβ42/Aβ40 Ratio , 2007, Journal of Biological Chemistry.

[76]  D. Ishii,et al.  Systemic insulin‐like growth factor‐I administration prevents cognitive impairment in diabetic rats, and brain IGF regulates learning/memory in normal adult rats , 2003, Journal of neuroscience research.

[77]  S. Plesneva,et al.  Effects of ageing and experimental diabetes on insulin-degrading enzyme expression in male rat tissues , 2015, Biogerontology.

[78]  N. Calcutt,et al.  The Roles of Streptozotocin Neurotoxicity and Neutral Endopeptidase in Murine Experimental Diabetic Neuropathy , 2010, Experimental diabetes research.

[79]  A. Mizisin,et al.  Diabetes induces changes in ILK, PINCH and components of related pathways in the spinal cord of rats , 2010, Brain Research.

[80]  A. Pfeiffer,et al.  Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cells , 2009, Diabetologia.

[81]  L. Morelli,et al.  The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme , 2008, Prion.

[82]  Sarah A. Stern,et al.  The effect of insulin and insulin-like growth factors on hippocampus- and amygdala-dependent long-term memory formation , 2014, Learning & memory.

[83]  M. Reger,et al.  Intranasal insulin improves cognition and modulates beta-amyloid in early AD. , 2008, Neurology.

[84]  M. Ohno,et al.  Mechanisms Underlying Insulin Deficiency-Induced Acceleration of β-Amyloidosis in a Mouse Model of Alzheimer's Disease , 2012, PloS one.

[85]  C. Bogardus,et al.  A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. , 2000, Diabetes.

[86]  C. Östenson,et al.  The Type 2 Diabetes–Associated Gene Ide Is Required for Insulin Secretion and Suppression of α-Synuclein Levels in β-Cells , 2013, Diabetes.

[87]  V. Vingtdeux,et al.  CALHM1 ion channel elicits amyloid-β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain , 2015, Journal of Cell Science.

[88]  W. Pories Hyperinsulinism as the culprit: surgery provides the evidence , 2012 .

[89]  J. Cresto,et al.  Degradation of Soluble Amyloid β-Peptides 1–40, 1–42, and the Dutch Variant 1–40Q by Insulin Degrading Enzyme from Alzheimer Disease and Control Brains , 2000, Neurochemical Research.

[90]  Kristine Yaffe,et al.  Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.

[91]  D. Selkoe,et al.  Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. , 2004, The American journal of pathology.

[92]  J. Luchsinger The Relationship Between the Continuum of Elevated Adiposity, Hyperinsulinemia, and Type 2 Diabetes and Late-onset Alzheimer’s Disease: An Epidemiological Perspective , 2010 .

[93]  John Wilding,et al.  Obesity and Diabetes , 2010, Experimental and Clinical Endocrinology & Diabetes.

[94]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[95]  Mark T. W. Ebbert,et al.  Genetics of Alzheimer's Disease , 2013, BioMed research international.

[96]  U. Meyer,et al.  Amylin at the interface between metabolic and neurodegenerative disorders , 2015, Front. Neurosci..

[97]  G. Schellenberg,et al.  Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.

[98]  D. Selkoe,et al.  Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin , 2010, PloS one.

[99]  J. Mcdermott,et al.  Degradation of Alzheimer's beta-amyloid protein by human cathepsin D. , 1996, Neuroreport.

[100]  Sarah A. Stern,et al.  A critical role for IGF-II in memory consolidation and enhancement , 2011, Nature.

[101]  K. Rockwood,et al.  Diabetes mellitus and the Risk of Dementia, Alzheimer’s Disease and Vascular Cognitive Impairment in the Canadian Study of Health and Aging , 2002, Dementia and Geriatric Cognitive Disorders.

[102]  S. McGuire,et al.  Centers for Disease Control and Prevention. State indicator report on Physical Activity, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014. , 2014, Advances in nutrition.

[103]  Hyoung-Gon Lee,et al.  Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition , 2014, Neurobiology of Aging.

[104]  J. Wands,et al.  Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed , 2008, Journal of diabetes science and technology.

[105]  J. Trojanowski,et al.  Interactions of amyloidogenic proteins , 2007, NeuroMolecular Medicine.

[106]  E. Masliah,et al.  Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice , 2010, Experimental Neurology.

[107]  I. Kurochkin Amyloidogenic determinant as a substrate recognition motif of insulin‐degrading enzyme , 1998, FEBS letters.

[108]  C. Soto,et al.  Are Amyloids Infectious , 2009 .

[109]  S. Monte Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer’s Disease , 2012, Drugs.

[110]  C. Soto,et al.  Cross currents in protein misfolding disorders: interactions and therapy. , 2009, CNS & neurological disorders drug targets.

[111]  R. Green,et al.  Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. , 2006, Archives of neurology.

[112]  C. DeCarli,et al.  Amylin deposition in the brain: A second amyloid in Alzheimer disease? , 2013, Annals of Neurology.

[113]  M. Folstein,et al.  Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis , 2006, Neurobiology of Aging.

[114]  J. Schneider,et al.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.